The results of a phase II study that was conducted to evaluate Relatlimab combination with Nivolumab (anti-PD-1) were associated with antitumor response in metastatic melanoma, and further studies are ongoing (NCT03743766) [143]. Here, PDCD1 is linked to metastatic melanoma.